Mankind Pharma faces Rs 183 crore tax demand, plans to appeal

Mankind Pharma has received tax demand orders from the Income Tax Department for Assessment Years (AY) 2014-15 to 2017-18, amounting to ₹183.11 crore, including interest. The demand arises from the disallowance of various expenditures under Section 37(1) of the Income-tax Act, 1961.

According to a regulatory filing, the orders were issued by the Office of the Deputy Commissioner of Income Tax, Central Circle 29, New Delhi.

The orders for AY 2014-15 and 2016-17 were dated March 24, 2025, while those for AY 2015-16 and 2017-18 were dated March 25, 2025. The company received the orders through the IT portal on March 28, 2025.

Mankind Pharma has said that it believes the tax demand is not legally justified and that it has strong factual and legal grounds to challenge the order. The company also asserted that the order is not expected to have any material impact on its financials or operations.

The pharmaceutical firm plans to appeal the order under applicable laws. Investors will be monitoring the situation closely as the company navigates this tax challenge.

Related Posts

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal, Ajinomoto team on ADC development and manufacturing

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Cancer cure must not be hostage to Big Pharma

Cancer cure must not be hostage to Big Pharma

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India